INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by the outgrowth of immature T-cells, 1 with Notch1 mutations being the most prominent genetic alteration in this disease (60% of cases). 2 In mice, constitutive Notch1 activation through the ectopic expression of the Notch1 intracellular fragment (N1IC) is sufficient to induce T-cell leukemia. 3 However, activating mutations found in human T-ALL samples are not powerful enough to reproduce T-ALL in mice, 4, 5 suggesting that Notch dose and/or other signals are also required for cell transformation. Supporting this concept, inactivating mutations of the E3 ubiquitin ligase FBXW7, which regulates N1IC stability, are commonly found in T-ALL patients, 6 as well as a diversity of genetic lesions, including the cell cycle regulator CDKN2A and the transcription factors TAL1/2, LYL1, LMO1/2, TLX/HOX, MYB and MYC. 7 Moreover, roles for phosphatase and tensin homolog (PTEN)/phosphoinositide-3 kinase, 8 Cyclin/cyclin-dependent kinase, 9 RAS, 5 interleukin-7R 10 and nuclear factor-κB 11 in Notch-dependent T-cell leukemia have been demonstrated.
The Wnt/β-Catenin (CTNNB1; catenin (cadherin-associated protein), beta 1, 88 kDa) pathway is a prevalent modulator (either activating or repressing) of Notch-dependent cell decisions. 12 Moreover, β-Catenin is a constitutive element of the cellular adherens junctions and, similarly to Notch, is involved in the integration of cell-to-cell signals. Under basal conditions, free β-Catenin is efficiently degraded by the proteasome downstream of the APC/AXIN/GSK3β destruction complex. In the presence of Wnt factors, the destruction complex is inhibited leading to the accumulation of β-Catenin, which translocates to the nucleus to activate specific gene transcription in association with the DNA-binding factors of the TCF/LEF family. 13 Ectopic activation of β-Catenin in the T-cell compartment induces a leukemic phenotype, 14 which is associated with an increased genomic instability. 15 β-Catenin-dependent transcription is essential for the maintenance of stem cell function in different tissues. 16, 17 To a lesser extent, β-Catenin also regulates stem cell self-renewal in the hematopoietic system, 18 and it maintains leukemic-initiating cells (LICs) in chronic myelogenous leukemia and acute myelogenous leukemia. 19 In T-ALL, LIC activity has been associated with cells that contain and require Notch, 20 myc 21 and, more recently, β-Catenin and hypoxia-inducible factor-1a. 22 In addition, β-Catenin has been identified as a crucial element for Notchindependent, PTEN-null-induced T-cell leukemia. 23, 24 Taken together, these findings underline the relevant role of Notch, β-Catenin and Myc in T-ALL.
We have here investigated the mechanism by which β-Catenin contributes to LIC regulation in Notch-induced T-ALL murine models and its possible use as therapeutic target for leukemia.
MATERIALS AND METHODS

Mouse models
Ef1a-Lox-Stop-Lox-Notch1IC, 25 VavCre 26 and β-Catenin-fl/fl 27 mice were crossed as indicated. Animal work adhered to the guidelines from Generalitat de Catalunya and the ethics committee at Parc de Recerca Biomèdica de Barcelona.
Antibodies, fluorescence-activated cell sorter (FACS) analysis and sorting CD117 (c-kit; APC-Cy7 or APC-eFluor780), sca1 (PE-Cy7), CD150 (APC), CD48 (PE), Lineage (CD3, Ter119, B220, Gr1; Biotin), streptavidin-PerCP-Cy5.5, CD4 (PE-Cy7), CD8a (PE), CD45.1 (APC-Cy7) and CD45.2 (FITC) antibodies were purchased from BD (Franklin Lakes, NJ, USA). DAPI (4,6-diamidino-2-1 Recombinant retroviruses or lentiviruses were produced according to standard protocols. Bone marrow (BM) was lineage-depleted (CD3, B220, Mac-1, Gr-1, Ter-119, BD Pharmingen) with Midi-MACS (Miltenyi Biotec, Bergisch-Gladbach, Germany). Lin − cells were cultured for 24 h with 10% fetal calf serum, 1% Penicillin/Streptomycin, 55 μM β-Mercaptoethanol, stem cell factor 50 ng/ml, Flt3L 50 ng/ml, interleukin-6 10 ng/ml, interleukin-7 10 ng/ml and then infected with pMIG-N1IC-GFP or pMIG-GFP. A short-hairpin RNA vector against β-Catenin (shβCat; pLKO.1-Hygro, target sequence TCTAACCTCACTTGCAATAAT, Sigma (St Louis, MO, USA) Mission shRNA ID no. TRCN0000314921) or scrambled control (shCtrl; GTCACGATAAGACAATGAT) were previously described. 28 Briefly, T-ALL cell lines were infected and selected for 3 days with hygromycin (400-800 μg/ml; Hygromycin B Gold, Invivogen, San Diego, CA, USA).
Transplantation experiments
Donor cells (CD45.2) were transplanted together with 200 000 BM support cells (CD45.1) into lethally irradiated (4+4 Gy) recipients (CD45.1). Peripheral blood (PB) donor chimerism was analyzed by FACS at 3-4 and 6-8 weeks. In vivo PKF115-584 treatment was administered through intraperitoneal injections (25-50 mg/kg) every 2-3 days.
Cell lysates, western blotting (WB) and immunoprecipitation
Cells were lysed in 20 min at 4°C in phosphate-buffered saline plus 0.5% Triton X-100, 1 mM EDTA, 100 mM Na-orthovanadate and protease inhibitors (Roche, Basel, Switzerland). For cytoplasm/nuclear/chromatin separations, 10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.05% NP40 at pH 7.9, 10 min on ice and centrifuged at 13 000 r.p.m. Supernatants were recovered and pellets lysed in 5 mM HEPES, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol and 26% glycerol and sonicated three times. Lysates were analyzed by WB. β-Catenin (c2206, Sigma), cleaved Notch1 (no. 2421, Cell Signaling Technology, Danvers, MA, USA) and Kaiso (ab12723, Abcam, Cambridge, MA, USA) antibodies were used.
For immunoprecipitations, cells were lysed 30 min at 4°C in 300 μl phosphate-buffered saline plus 0.5% Triton X-100, 1 mM EDTA, 100 mM Na-orthovanadate, 0.25 mM PMSF and complete protease inhibitor cocktail (Roche). After centrifugation, supernatants were precleared 2 h with 1% of bovine serum albumin, 1 μg IgGs and 50 μl SPA beads. Precleared lysates were incubated overnight with 3 μg of the indicated antibodies (Irrelevant IgG or anti-β-Catenin (BD Biosciences, San Jose, CA, USA, catalog no. 610154) or cleaved Notch1 (ab8925, Abcam)). Antibody-protein complexes were captured with 30 μl SPA beads for 2 h. After washing, precipitates were analyzed by WB.
Chromatin immunoprecipitation
Chromatin from crosslinked cells (0.5% formaldehyde, 10 min) was sonicated, incubated overnight with N1IC (kindly provided by J Aster) or β-Catenin (BD Biosciences, 610154) antibodies and precipitated with protein G/A-Sepharose, reverse crosslinked and used for quantitative PCR (QPCR; primers in Supplementary Table S1 ).
Cell lines and drug treatments
All cell lines were cultured in standard conditions (RPMI-1640+10% fetal bovine serum, Invitrogen). Inhibitors were resuspended in dimethyl sulfoxide (DMSO) in various concentrations: PKF115-584 (a gift from Novartis, Basel, Switzerland) at 10 nM-1 μM, N-S-phenyl-glycine-t-butyl ester (DAPT; Calbiochem) at 5-50 μM and Pyrvinium (Sigma) at 31 nM-1 μM in different experiments. Cell number and viability were assessed using DAPI (D1306, Invitrogen) by FACS (LSRII, BD).
Luciferase assays
T-ALL cell lines were electroporated with the 3′ myc reporter (N-Me) 29 plasmid at 250 V, 1050 μF with Gene Pulser II (Bio-Rad, Hercules, CA, USA) and treated with DMSO, 25 μM DAPT, 310 nM PKF115-584 or DAPT+PKF115-584 or were untreated in the case of hygromycin-selected shRNAtransduced T-ALL cells. DMSO/DAPT were added after electroporation, and at 24 h, the medium was replaced with new DAPT and/or PKF115-584. Luciferase activity was measured after 48 h (Luciferase Assay System, Promega, Fitchburg, WI, USA). Values were normalized to β-galactosidase (co-electroporation of CMV-β-Gal plasmid) or total protein (Bradford Assay).
Next-generation sequencing analyses
Libraries created from polyA+ mRNA from four T-ALL cell lines (+DMSO or +PKF115-584) were sequenced on a Solexa HiSeq 2000 (Illumina, San Diego, CA, USA) and yielded 20-35 million 50-nt single-end reads per sample. Reads were mapped to the human GRCh38.77 genome assembly with TopHat, and the RNASeq expression data were obtained using the Cufflinks suite.
Statistics
Data were plotted and statistics was calculated using GraphPad Prism 6.07 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Transgenic Notch1-IC drives the expansion of LSKCD150 − CD48+ LICs in the fetal liver (FL) To study the early stages of Notch1-driven T-ALL, we set up a transgenic mouse model utilizing the Ef1a-Lox-Stop-Lox-Notch1IC (N1IC LSL ) mouse line 25 crossed to VavCre-deleter mice. 26 VavCre +N1IC LSL (here N1IC+) embryos were embryonic lethal after E14.5 (Supplementary Figure S1A) . Analysis of E14. Figure S1F ) indicative of leukemic growth, and all LSK and most Lin − Sca − Kit+ receiving recipients succumbed to T-ALL with a median survival of ≈7 weeks (Figure 1f ).
These data demonstrate that Notch1 activation in the fetal hematopoietic compartment leads to the expansion of a phenotypically defined cell population with robust LIC activity upon transplantation, thus providing a good model for a mechanistic investigation of T-ALL initiation by Notch.
β-Catenin levels determine the leukemic-initiation capacity of Notch1-induced leukemia As β-Catenin has important roles in HSC generation and selfrenewal as well as in many types of cancer, we sought to β-Catenin and Notch drive T-ALL C Gekas et al To investigate whether β-Catenin was functionally relevant in the N1IC+ LICs, we analyzed triple transgenic VavCre+N1IC+βCatKO embryos. Similar levels of E14.5 FL cellularity reduction, expansion of the FL LSK CD150-CD48+ population and embryonic lethality were observed in N1IC+ embryos irrespective of β-Catenin status (Figures 2b and c, Supplementary Figures  S2A-C) . By QPCR analysis, we detected variable levels of residual β-Catenin expression among individual N1IC+βCat fl/fl samples, ranging from ≈2-5% (termed Δ/fl) to o0.1% (termed Δ/Δ) compared with control N1IC+βCat fl/+ samples (100%, termed Δ/+) (Figure 2d) . We next performed transplantation experiments using 1000 or 5000 unfractionated FL cells from N1IC+βCat
and N1IC+βCat
Δ/Δ embryos and analyzed donor chimerism and DP cells at 3 weeks by FACS (Figure 2e ). We found that N1IC+βCat Δ/+ as well as N1IC+βCat Δ/fl but not N1IC+βCat Δ/Δ transplanted animals yielded substantial levels of DP cells ( Supplementary  Figures S2D and E) . Importantly, levels of residual β-Catenin expression in the donor cells significantly correlated with donor chimerism in the recipient mice (Figure 2f ) and the number of functional LICs in the transplanted population (Figure 2g ), Specifically, we estimated LIC frequencies of 1 in 600 FL cells for N1IC+βCat Δ/+ , 1 in 2800 for N1IC+βCat Δ/fl and 1 in 6000 for N1IC+βCat Δ/Δ (Figure 2g) . Moreover, whereas all N1IC +βCat Δ/+ cell recipients succumbed to T-ALL within a period of 9 weeks, animals transplanted with N1IC+βCat
Δ/fl and, to a higher extent, with N1IC+βCat
Δ/Δ cells displayed improved survival for up to 1 year (log-rank test for trend P = 0.0068) (Figure 2h and Supplementary Figure S2F ). These results demonstrate a functional requirement for β-Catenin in Notch-induced T-ALL LICs.
β-Catenin deletion in adult hematopoietic cells abrogates Notch-driven T-ALL To achieve a consistent complete β-Catenin deletion, we next utilized an independent model of Notch T-ALL. Briefly, lineage-depleted BM cells (Lin − BM) from VavCre + βCat +/+ and VavCre + βCat fl/fl mice were transduced with mock pMIG-GFP (+pMIG) or pMIG-N1IC-GFP (+N1IC) retroviral vectors and transplanted into lethally irradiated recipients (Figure 3a ). Mice transplanted with βCat +/+ +N1IC cells developed T-ALL with marked accumulation of blood DP cells within 3-4 weeks (Figures 3b and c) , as previously described. 3 In contrast, animals transplanted with βCat fl/fl +N1IC cells did not contain detectable levels of DP cells at any time point analyzed (Figures 3b and c) despite comparable engraftment levels (%GFP+) at 3-4 weeks (Figure 3d ). In agreement with this, βCat +/+ +N1IC-derived chimerism increased between 3-4 and 6-8 weeks, while βCat fl/fl +N1IC-derived chimerism remained constant, similarly to that observed in the mock-infected (βCat fl/fl +pMIG) controls (Figure 3d) . Importantly, animals receiving βCat fl/fl +N1IC cells survived for the duration of the study (46 months), whereas βCat +/+ +N1IC recipients invariably succumbed, with a median survival of ≈9 weeks (Figure 3e) . Persistence of N1IC vector in the unfractionated and FACS-sorted CD4 +CD8a+ DP thymic cell population from both β-Catenin genotypes was confirmed at the study end point (Supplementary Figure S3) .
β-Catenin inhibitor PKF115-584 induces apoptosis and reduces proliferation in human T-ALL cells
We next investigated the status of β-Catenin in human T-ALL. By WB analysis, we observed elevated levels of β-Catenin in T-ALL cell lines carrying cleaved Notch1 (N1IC), compared with the relatively low β-Catenin levels found in myeloid and B-cell leukemic lines (Supplementary Figure S4A) . Further analysis of four T-ALL lines (RPMI8402, HPB-ALL, Jurkat, CCRF-CEM, referred to as 4T-ALL) showed cytoplasmic and nuclear accumulation of both N1IC and β-Catenin (Figure 4a ), suggesting that both factors are active in T-ALL. To test whether β-Catenin was functionally required in human T-ALL, we utilized a small molecule, PKF115-584, previously shown to inhibit the transcriptional activity of β-Catenin. 31 We found that PKF115-584 rapidly (16-24 h of treatment) and permanently affected the cell number kinetics of all tested cell lines (Figure 4b and Supplementary Figure S4B ), mainly as a result of increased cell death and reduced proliferation, as determined by AnnexinV/DAPI and Ki67 staining, (Figures 4c and d) . A comparable cytotoxic effect on T-ALL cells was observed after treatment with pyrvinium, also known to inhibit β-Catenin activity in vivo 32 (Supplementary Figure S4C ).
Myc is a direct target of Notch and β-Catenin in T-ALL that is inhibited by PKF115-584 and shRNA against β-Catenin
To further understand the mechanism underlying β-Catenin function in T-ALL cells, we treated four T-ALL cell lines (4T-ALL) with PKF115-584 or DMSO for 3 h and performed RNA-Sequencing (Figure 5a ). Gene set enrichment analysis (GSEA) on the differentially expressed genes across all four lines (false-discovery rate q-value o 0.01, log2 FC ⩾ 0.4, FPKM ⩾ 5) showed significant downregulation of oxidative phosphorylation and MYC target gene sets (Figures 5b and c and Supplementary Figures S5A-C) . In contrast, gene categories associated with apoptosis and stress response (for example, p53 pathway, nuclear factor-κB) were significantly upregulated (Figures 5b and c and Supplementary Figure S5D ). Selected genes from MYC targets or apoptosis categories were validated by QPCR (Figure 5d and Supplementary Figure S5E) . Notably, MYC mRNA and protein levels were rapidly (2-3 and 24 h, respectively) downregulated in all four T-ALL lines in response to PKF115-584 (Figures 5d and e and Supplementary  Figures S5E and F) , while Notch activity, as estimated by Hes1 mRNA expression or GSEA analysis against Notch-responsive gene sets, was unaffected (Figure 5e and Supplementary Figure S5G) . Pyrvinium was also efficient at downregulating Myc protein levels, albeit while also broadly downregulating β-Catenin and Notch1-IC levels, in contrast to PKF115-584 (Supplementary Figure S5F) .
Because of its relevance in several cancer models, we studied the possible regulation of MYC by Notch and β-Catenin in T-ALL. To confirm the role of β-Catenin, we utilized sh-control (shCtrl) or sh-β-Catenin (shβCat) lentiviruses to efficiently target β-Catenin at both mRNA and protein levels in T-ALL cell lines (Figures 5f and g ). We observed increased levels of cell death and apoptosis while cell growth was differentially affected in the different T-ALL cell lines tested (Supplementary Figures S6A and B and data not  shown) . Importantly, knockdown of β-Catenin led to a decrease of MYC mRNA and protein levels (Figures 5f and g) . Similarly to what was observed with PKF115-584, Hes1 was not downregulated indicating that Notch activity was not affected despite a decrease in protein levels of active Notch observed in shβCat-infected T-ALL cells (Figures 5f and g ).
By chromatin immunoprecipitation using antibodies against β-Catenin, N1IC and RBPj in two different T-ALL cell lines (Jurkat and CCRF-CEM), we did not detect any binding in the MYC promoter (Figure 5h ), which contain WRE/TCF/LEF-binding sites that associate with β-Catenin in other tissues. 33 In contrast, we found that the recently identified 3′ MYC enhancer (MYC-Enh), known to bind Notch1, 29, 34 also showed a significant enrichment for β-Catenin occupancy (Figure 5f ). As we found, by co-immunoprecipitation in Jurkat and RPMI8402 cells, that Notch1 physically interacted with β-Catenin (Figure 5i and Supplementary Figure S5H) , we hypothesized that β-Catenin may be recruited to this site by direct interaction with Notch1 as in other double Notch/β-Catenin targets. 35, 36 To test whether Notch1 and β-Catenin were necessary for MYC enhancer activity, we transfected the 3′ enhancer cloned in a luciferase reporter vector 29 into Jurkat cells, which were either untreated (DMSO) or treated overnight with DAPT (a γ-secretase/Notch inhibitor), PKF115-584 or DAPT+PKF115-584. As previously described, 29 we observed a decrease of luciferase activity by DAPT (Figure 5j ; left panel). Of note, treatment of cells with PKF115-584 also significantly reduced the luciferase activity of the Myc-enhancer construct, and the DAPT+PKF115-584 combination showed an almost complete (≈98%) inhibition of enhancer activity (Figure 5j; left panel) . In addition, a significant decrease in the Myc enhancer transcriptional activity was measured in RPMI8402 cells previously transduced with shβCat compared with shCtrl (Figure 5j; right panel) .
These results indicate that the interaction between β-Catenin and Notch1 is important for maintaining the oncogenic program in T-ALL, at least in part through co-regulation of MYC transcription through its 3′ enhancer. 
PKF115-584 treatment inhibits survival of T-ALL leukemic cells in vivo
To test the possibility of using PKF115-584 to treat leukemia in vivo, we used our FL transplantation model. E14.5 FL cells from N1IC+ embryos were transplanted together with BM competitor cells into lethally irradiated mice (Figure 6a ). Recipient mice were randomly grouped into three regimens: Animals treated with PKF115-584 by intraperitoneal injection every 2 days, (i) for 6 weeks starting at day 3 posttransplantation (PKF0-6), (ii) 3 weeks of treatment starting at week 3 (PKF3-6) or (iii) animals were left untreated (Figure 6a ). FACS analysis of PB at 3 weeks showed a significant reduction in donor chimerism (≈50%, P = 0.003) in the cohort treated with PKF115-584 compared with untreated recipients (Figure 6b ). In contrast, PKF115-584 had no significant effect on wild-type total leukocyte counts (white blood cell), indicating that the drug specifically targeted leukemic N1IC+ cells (Figure 6c ). In support of the requirement for β-Catenin activity in leukemia initiation, mice in the PKF0-6 cohort displayed significantly improved overall survival and a delay in leukemic death onset compared with untreated mice (Figure 6d) . Finally, although not statistically significant (P = 0.22), PKF115-584 treatment for 3 weeks (cohort PKF3-6) prevented death for ⩾ 40 weeks of 22% of mice with confirmed initial CD4+CD8a+ DP leukemic burden (DP+) (Figure 6e and data not shown), in contrast with DP+ untreated recipients that invariably succumbed to T-ALL by 9 weeks.
In summary, these data nominate β-Catenin as a promising therapeutic target in T-ALL treatment.
DISCUSSION
Despite increasing evidence for the roles of Notch and β-Catenin in tissue maintenance, stem cell self-renewal and cancer, separate findings from different groups yield seemingly contradictory results, with Wnt and Notch acting synergistically or antagonistically depending on cellular/tissue context (reviewed in Collu et al. 37 ). In this study, we found an essential crosstalk between Notch1 and β-Catenin in T-ALL through direct regulation of MYC, consistent with the association of these three proteins with LIC activity in T-ALL. [20] [21] [22] In addition, mutations in other pathways such as PTEN may determine the levels of β-Catenin activity, 23 which would affect Notch-induced leukemogenic potential as shown in our murine model, although we did not observe any correlation between PTEN mutations in T-ALL cell lines and total β-Catenin levels. However, more work should be carried out to specifically address this issue and understand the relevance of PTEN in this connection.
The Wnt pathway has long been associated with T-cell development and T-cell leukemia; 14, [38] [39] [40] however, the specific role of particular Wnt-pathway family members remains highly controversial. For example, LEF1 and TCF7 (also known as TCF-1) nuclear factors regulate T-cell differentiation but they can either act as leukemia/lymphoma inducers or suppressors in a contextdependent manner. Published data demonstrated that TCF7 acts as tumor suppressor by inhibiting LEF1, but in turn inactivating LEF1 mutations were also found to result in T-ALL associated with MYC gene upregulation, 38 with Notch1 activity being crucial for the leukemic process driven by either TCF7 or LEF1 inactivation. 39, 40 Whether leukemia development requires β-Catenin in these LEF/TCF-deficient systems remains unknown. Our analysis of the MYC regulatory regions revealed that both Notch1 and β-Catenin associate in the same region of 3′ MYC enhancer, containing three well-defined RBPj consensus sites, whereas binding was not observed for either factor in the MYC promoter containing a TCF/LEF-binding motif. The fact that β-Catenin physically interacted with cleaved Notch1 in T-ALL cells by co-immunoprecipitation under conditions where DNA is not detected supports the possibility that β-Catenin binds DNA through an RBPj/Notch1 complex. In agreement with this, we found that both proteins positively regulate the 3′ MYC enhancer, and MYC mRNA levels as well as MYC targets were significantly reduced after PKF115-584 treatment in T-ALL cells. Further work comparing the DNA-binding activity of β-Catenin and Notch1 in a genome-wide approach will help to elucidate the /l). **P o0.01 by unpaired t-test. (d and e) Survival curves for cohorts untreated or treated with PKF for 6 (d) or 3 (e) weeks. In panel (e), only mice with confirmed leukemic burden (⩾1% CD4+CD8a+ DP cells in PB at 3 weeks) are included. Data are from three independent experiments. *P = 0.0146 by log-rank (Mantel Cox) test and P = 0.0059 by Gehan-Breslow-Wilcoxon test.
β-Catenin and Notch drive T-ALL C Gekas et al specific contribution of β-Catenin to Notch1-dependent gene transcription. Consistent with a prominent role of β-Catenin in leukemogenesis, we have here shown that PKF115-584 efficiently inhibited cell growth and induced apoptosis in T-ALL cells. In fact, in our assay, PKF115-584 was a more potent inhibitor of MYC enhancerdependent transcription than the γ-secretase inhibitor DAPT. This was dependent on dose and time of incubation, although we cannot exclude that PKF115-584 is targeting other proteins than just β-Catenin. In this sense, our in vivo genetic studies, as well as our in vitro depletion of β-Catenin by a single shRNA previously shown to efficiently inhibit β-Catenin, 28 confirm that T-ALL cells strongly rely on β-Catenin for MYC expression and survival. In vivo, mice transplanted with Notch1-active T-ALL progenitors (LICs) that received PKF115-584 treatment 3 days after the initiation of the experiment showed increased survival compared with control leukemic animals. However, mice treated from week 3 after transplantation did not show a significantly different survival, but 22% of the animals carrying double CD4+CD8a+ double-positive cells at week 3 posttransplantation remained alive after 40 weeks, compared with 100% lethality in the control group by week 9. These results suggest that PKF115-584 was affecting not only leukemia initiation, as recently shown for β-Catenin, 22 but also maintenance, which is relevant from a therapeutic point of view. Most importantly, normal hematopoietic cells were refractory to the in vivo PKF115-584 treatment, indicating a differential sensitivity of leukemic and normal cells toward β-Catenin inhibition.
Together our data indicate that Notch depends on β-Catenin for the leukemogenic activity associated with MYC upregulation and identifies β-Catenin as a promising therapeutical target for T-ALL.
